Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
NeuroOne Medical Technologies Corporation is a medical device company focused on the development and commercialization of thin‑film electrode technologies used in neurological diagnostics and therapeutic procedures. The company operates within the medical devices and neuromodulation industries, with a primary emphasis on products used in epilepsy monitoring, brain mapping, and neurosurgical intervention. Its core offerings are designed for minimally invasive recording, stimulation, and ablation in the brain, targeting hospitals and specialized neurological centers.
The company’s primary revenue drivers are its proprietary thin‑film electrode products, including cortical and stereoelectroencephalography (sEEG) electrodes, as well as systems that enable diagnostic monitoring and therapeutic procedures. NeuroOne positions itself through differentiated thin‑film technology that emphasizes flexibility, reduced invasiveness, and compatibility with advanced neurosurgical workflows. Founded in 2009 and headquartered in Minnesota, the company evolved from a research‑driven enterprise into a publicly traded medical technology company following its initial public offering in 2021.
Business Operations
NeuroOne generates revenue through the sale of neurosurgical electrodes and related systems used in epilepsy diagnosis and treatment, functional brain mapping, and emerging therapeutic applications. Its operations are organized around a single integrated business focused on neurosurgical device development and commercialization, rather than multiple reporting segments. Key product lines include Evo® Cortical Electrodes, Evo® sEEG Electrodes, and the NeuroOne OneRF® Ablation System, which enables radiofrequency ablation using the company’s thin‑film sEEG electrodes.
Operations are primarily domestic, with manufacturing, research and development, and corporate functions based in the United States. The company controls its core thin‑film electrode technology and maintains quality and regulatory oversight consistent with U.S. Food and Drug Administration requirements. NeuroOne sells directly to U.S. hospitals and epilepsy centers and utilizes distributor relationships for certain international markets. Public disclosures identify NeuroOne, Inc. as its principal operating subsidiary.
Strategic Position & Investments
NeuroOne’s strategic direction centers on expanding the clinical utility of its thin‑film electrode platform beyond diagnostics into therapeutic applications. A key growth initiative has been the development and regulatory clearance of the NeuroOne OneRF® Ablation System, which allows physicians to perform lesioning procedures using the same electrodes deployed for brain monitoring, potentially reducing procedural complexity and cost.
The company continues to invest in research and development aimed at additional indications such as chronic pain and movement disorders, as well as enhancements to electrode durability and performance. NeuroOne’s strategy emphasizes organic growth rather than large-scale acquisitions, and publicly available filings do not indicate significant completed acquisitions as of the most recent reporting periods. Any future investments or partnerships beyond disclosed distributor relationships are not clearly verifiable based on available public sources.
Geographic Footprint
NeuroOne is headquartered in North America, with its principal offices and operations located in Minnesota, United States. The United States represents its largest market, driven by a high concentration of comprehensive epilepsy centers and advanced neurosurgical facilities.
Internationally, the company has established a limited but growing presence through distributor agreements in parts of Europe and other select regions. While NeuroOne does not maintain extensive foreign manufacturing or regional headquarters, its products are marketed globally where regulatory approvals and distribution partnerships are in place. Data regarding revenue contribution by individual non‑U.S. countries is inconclusive based on available public sources.
Leadership & Governance
NeuroOne is led by an executive team with experience in medical devices, neuromodulation, and public company operations. The company was founded by David V. Hokanson, who played a central role in the early development of its thin‑film electrode technology and previously served in executive leadership roles.
Current leadership emphasizes disciplined commercialization, regulatory compliance, and the expansion of clinical indications for the company’s technology platform. Key executives include:
- Dave Rosa – President and Chief Executive Officer
- Chris Eggert – Chief Financial Officer
- Patrick O’Leary – Vice President of Sales (title and scope based on public disclosures; exact responsibilities may vary)
The board of directors provides governance oversight consistent with U.S. public company standards, with a strategic focus on long‑term value creation through innovation in neurosurgical care.